FindTrial
Sign In

Cyclophosphamide, fludarabine

DRUG2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Huazhong University of Science and Technology

Conditions

CD5+ Relapsed/Refractory Hematopoietic MalignanciesChronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Fanconi AnemiaFollicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Peripheral T-cell Lymphomas (PTCL)

Early Phase 1

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
NCT04767308
Huazhong University of Science and TechnologyCD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL) +3
Start: 2021-03-31End: 2023-12-31Target: 18Updated: 2021-02-23

Phase 1

Stem Cell Transplantation for Fanconi Anemia
TerminatedNCT00167206
Masonic Cancer Center, University of MinnesotaFanconi Anemia
Start: 2004-03-31End: 2008-12-31Updated: 2019-08-26

Related Papers

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies
Blood2025-11-03
Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma
Frontiers in Immunology2023-12-086 citations
Alternative donor hematopoietic cell transplantation for Fanconi anemia
Blood2015-04-01106 citations